Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Indian Panel Reviews Celsentri Clearances

Executive Summary

An Indian expert panel has sought data on ViiV Healthcare's HIV entry inhibitor maraviroc (Selzentry/Celsentri) - among the drugs cleared, some years ago, with a trial waiver in the country and recommended for re-examination by a Parliamentary committee.

Advertisement

Related Content

Indian regulator in cahoots with industry and has 'skewed' priorities, says parliament
ViiV close to licensing out Celsentri in India; rules out compulsory licensing concerns

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC065431

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel